– USA, MD – Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy, today announced the appointment of Dr. Bette Jacobs (Ph.D.) to its Board as an independent director.
“I am excited to welcome Dr. Bette Jacobs to the board at Shuttle Pharmaceuticals. Her body of work spans community, academic, service, and corporate leadership, having been recognized for contributions to successful start-ups, financial integrity, and interdisciplinary innovations. I look forward to her guidance as we look to advance our clinical programs focused on improving outcomes for cancer patients,” said CEO, Dr. Anatoly Dritschilo.
Dr. Jacobs will also join the Audit Committee and the Nominating and Corporate Governance Committee.
About Dr. Bette Jacobs
Dr. Jacobs is a professor in the department of health systems administration at Georgetown University and a distinguished scholar at the O’Neill Institute for National and Global Health Law. She is noted for groundbreaking transdisciplinary and cross-sector work in system design. A voting member of the Cherokee Nation, Dr. Jacobs has a lifetime involvement in advancing equity and diversity programs.
Dr. Jacobs said, “I look forward to lending my experience to Shuttle Pharmaceuticals as it looks to accomplish the mission of improving the lives of cancer patients.”
Previously, Dr. Jacobs was dean at the Georgetown University School of Nursing and Health Studies, VP for Honda of America Manufacturing, founding faculty and associate director of applied research at UAB Civitan International Research Center, and acting dean of graduate studies and research at California State University. She has been a fellow and visiting professor at the University of Oxford Campion Hall and an academic guest scholar and lecturer for Chang Gung University, Anhui University, Tokyo Medical and Dental University, University of British Columbia, University of Sienna, Sciences Po, and the Karolinska Institute. In addition to serving on several start-up boards, Dr. Jacobs founded the National Coalition of Ethnic Minority Nurse Associations funded by the NIH National Institute of General Medical Sciences.
Dr. Jacobs’ current projects focus on faith-based health systems; decolonization and ecology; migration, indigeneity, and gender; missing and murdered people; and international indigenous rights. Dr. Jacobs earned her B.S. and M.S. from California State University and holds a Ph.D. from the University of Texas.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy. Our mission is to improve cancer patients’ lives by developing therapies designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or combined with surgery, chemotherapy, and immunotherapy.
For more information: https://shuttlepharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.